Top 40 Heart disease treatment startups in USA
May 30, 2026
|
Like
20
1
Funding: $3.8B
Verily Health is Alphabet's life science subsidiary, that works at the intersection of healthcare, research and technology and focuses on using AI for precision medicine. The company develops tools and platforms for disease prevention, diagnosis and management.
Verily Health is Alphabet's life science subsidiary, that works at the intersection of healthcare, research and technology and focuses on using AI for precision medicine. The company develops tools and platforms for disease prevention, diagnosis and management.
2
Funding: $2.4B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
3
Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
4
Funding: $733.3M
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
5
Funding: $603.2M
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
6
Funding: $554M
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures.
7
Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
8
Funding: $390.6M
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
9
Funding: $386.5M
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
10
Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
11
Funding: $337.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
12
Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
13
Funding: $290M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
14
Funding: $173.2M
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
15
Funding: $166.2M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
16
Funding: $154.3M
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
17
Funding: $145M
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
18
Funding: $141.4M
Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.
Capstan Medical is creating minimally invasive technologies to treat heart valve disorders.
19
Funding: $138.2M
Cutting-edge technology that empowers employees to improve heart health.
Cutting-edge technology that empowers employees to improve heart health.
20
Funding: $115M
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
21
Funding: $107.1M
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
22
Funding: $102M
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
23
Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
24
Funding: $39.4M
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
25
Funding: $77.9M
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
26
Funding: $56.3M
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
27
Funding: $53.5M
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
28
Funding: $53M
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
29
Funding: $46M
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
30
Funding: $41.9M
Atraverse Medical offers a product development for left-heart access technology to simplify workflows and improve patient outcomes.
Atraverse Medical offers a product development for left-heart access technology to simplify workflows and improve patient outcomes.
31
Funding: $31.6M
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
32
Funding: $27.8M
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
33
Funding: $14.1M
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
34
Funding: $12.5M
Vector is a cardiac digital health provider that makes it simple for care teams to capture, manage, analyze, and act on remote cardiac data.
Vector is a cardiac digital health provider that makes it simple for care teams to capture, manage, analyze, and act on remote cardiac data.
36
Funding: $11M
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
37
Funding: $8M
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
38
Funding: $8M
CardioOne is a physician-centric partner that helps independent cardiology practices reach their full potential.
CardioOne is a physician-centric partner that helps independent cardiology practices reach their full potential.
39
Funding: $8M
Chamber Cardio is a healthcare platform enhances cardiovascular health services.
Chamber Cardio is a healthcare platform enhances cardiovascular health services.
40
Funding: $4.7M
Vixiar Medical develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases.
Vixiar Medical develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases.
★
See also:
